1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


Delayed London Stock Exchange  -  11:38 2022-07-07 am EDT
11006.00 GBX   +0.26%
07:25aASTRAZENECA : Jefferies reiterates its Neutral rating
03:45aASTRAZENECA : JP Morgan reiterates its Buy rating
07/06China allows AstraZeneca's COVID preventive drug in southern city
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Indian vaccine giant Serum plans African plant in global expansion

05/24/2022 | 08:45am EDT
Poonawalla, CEO of Serum Institute of India  speaks during an interview in Davos

DAVOS, Switzerland (Reuters) - The Serum Institute of India (SII), the world's biggest vaccine maker, is considering setting up its first manufacturing plant in Africa as it looks to expand globally after its success in selling COVID-19 shots, its CEO told Reuters on Monday.

Africa was the only continent that did not have its own manufacturing capacity for COVID shots during the worst phases of the pandemic in the last two years, leaving it at the mercy of suppliers from overseas, including the SII.

"It's never been a better time to be a vaccine manufacturer. I'm looking at expanding our manufacturing across the globe," SII Chief Executive Adar Poonawalla said during an interview at the World Economic Forum in Davos.

"There are some great countries out there: South Africa, Rwanda, you know, to name a few that we're looking at."

Poonawalla said he was meeting some African officials in Davos to discuss his plans. Asked about possible investments, he said such projects typically required at least around $300 million.

He did not say what products an African plant might make. Apart from COVID shots, the SII's Indian plants make vaccines for diphtheria, BCG, measles, rubella and other conditions.

Asked about concerns over the rise of monkeypox cases, Poonawalla said he believed the disease was not so infectious.

"We'll wait and see even if we want to make a vaccine for it," he said.

Monkeypox is usually mild and is endemic in parts of west and central Africa. The World Health Organization has said it expects to identify more cases as it expands surveillance in countries where the disease is not typically found.

On COVID, the SII has sold more than 1.5 billion doses in India of the AstraZeneca shot it makes and brands Covishield, and exported millions more.

But as demand has now waned, the company is putting its Indian Covishield facilities on standby and will "not produce anything there", Poonawalla said, while adding it could resume output if needed.

The SII has also pulled the plug on a plan to produce and sell about 300 million doses of Russia's Sputnik Light COVID vaccine. However, it is still making millions of doses of a version of the Novavax COVID shot for India and other countries, Poonawalla said.

He estimated privately held SII was now valued at roughly $20 billion, but said there was no immediate plan to go public.

(Reporting by Aditya Kalra in Davos Writing by Krishna N. Das; Editing by Mark Potter)

By Aditya Kalra

© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.26% 11006 Delayed Quote.26.41%
DOW JONES AFRICA TITANS 50 INDEX 2.56% 450.44 Real-time Quote.-18.77%
DOW JONES SOUTH AFRICA(ZAR) 3.22% 1926.56 Real-time Quote.-5.97%
NOVAVAX, INC. 14.62% 72.63 Delayed Quote.-55.59%
POONAWALLA FINCORP LIMITED 7.99% 248.6 Delayed Quote.4.99%
S&P AFRICA 40 INDEX 3.88% 145.16 Real-time Quote.-20.19%
SII 4.94% 42.5 Real-time Quote.-15.98%
All news about ASTRAZENECA PLC
07:25aASTRAZENECA : Jefferies reiterates its Neutral rating
03:45aASTRAZENECA : JP Morgan reiterates its Buy rating
07/06China allows AstraZeneca's COVID preventive drug in southern city
07/06Weak sterling boosts FTSE 100 amid political, growth worries
07/06UK stocks rebound as investors weigh political uncertainty
07/06Astrazeneca inks $1.2bn deal with US biotech firm
07/05European Bourses Hammered by Recession Fears; Euro Falls to 20-Year Low
07/05GLOBAL MARKETS LIVE : J Sainsbury, Foxconn, JPMorgan, Comcast, Tesla...
07/05ASTRAZENECA : Buy rating from Deutsche Bank
07/05AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager, strengthening ha..
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 43 688 M - -
Net income 2022 4 889 M - -
Net Debt 2022 24 402 M - -
P/E ratio 2022 41,0x
Yield 2022 2,26%
Capitalization 203 B 203 B -
EV / Sales 2022 5,19x
EV / Sales 2023 4,78x
Nbr of Employees 83 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Last Close Price 130,69 $
Average target price 141,41 $
Spread / Average Target 8,21%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC26.41%202 500
JOHNSON & JOHNSON4.13%469 179
PFIZER, INC.-12.55%295 975
ROCHE HOLDING AG-14.71%272 233
ABBVIE INC.12.65%269 537